{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.79","upperLimit":"54.61","value":"44.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The time to disease progression is calculated from the date of treatment. Data for patients who remain disease progression free are censored as of date when the last follow-up information is obtained.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy will be delivered using standard once-daily fractionation, five days a week for 8 weeks. Bevacizumab is administered intravenously once on day 1 every two weeks during the course of radiation and up to one year following completion of radiation therapy, at which point bevacizumab will be discontinued.Patients meeting planned neck dissection criteria, will not receive bevacizumab therapy following completion of concurrent chemo-radiation therapy (for at least 8 weeks prior to surgery). Bevacizumab therapy will restart 4 weeks after planned neck dissection for nine months.Docetaxel is administered intravenously once per week only during the course of radiation.","id":"OG000","title":"Bevacizumab With Docetaxel and Radiation Therapy"}],"paramType":"MEAN","populationDescription":"Patients who received at least one treatment on study","reportingStatus":"POSTED","timeFrame":"5 yrs after treatment","title":"Time to Progression","type":"PRIMARY","unitOfMeasure":"Months"}